- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06199375
Effect of Modified Mirror Therapy in Patients With Upper Limb Hemiparesis After Stroke
March 2, 2024 updated by: Zeng Changhao
The Clinical Effect of Modified Mirror Therapy in Patients With Upper Limb Hemiparesis After Stroke: A Randomized Controlled Study
This was a randomized controlled study in China conducted during Aug. 2022 to Aug. 2023.
Totally, patients with upper limb hemiplegia after stroke, who were admitted in the Department of Rehabilitation Medicine of two hospitals, were enrolled.
The study lasted 30 days for each participant.
The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy.
Additionally, the patients in the experimental group were given modified mirror therapy.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Upper limb hemiparesis is a motor and sensory disorder that occurs after stroke, with an incidence rate of up to 55% to 75%.
Effective upper limb rehabilitation methods help reduce the occurrence of disuse syndrome and complex regional pain syndrome.
Therefore, finding active and effective limb rehabilitation methods has important practical significance.This was a randomized controlled study in China conducted during Aug. 2022 to Aug. 2023.
Totally, patients with upper limb hemiplegia after stroke, who were admitted in the Department of Rehabilitation Medicine of two hospitals, were enrolled.
The study lasted 30 days for each participant.
The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy.
Additionally, the patients in the experimental group were given modified mirror therapy.
The assessment was conducted respectively on day 1 and day 30.
Study Type
Interventional
Enrollment (Actual)
116
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Zheng da yi fu yuan hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Meeting the diagnostic criteria of stroke, by CT or MRI.
- The first-onset stroke.
- Presenting with unilateral upper limb dysfunction, within Brunnstrom stage Ⅱ to Ⅳ on the affected side, and Ash-worth score ≤2.
- No obvious cognitive impairment, with Mini-Mental State Examination (MMSE) score >21 points.
- National Institutes of Health Stroke Scale (NIHSS) score >4 points.
- Stable vital signs, no severe diseases such as cancer, liver or kidney disorders.
- Aged 35-70 years.
- Courses of diseases 2-6 weeks.
Exclusion Criteria:
- Presence of aphasia, apraxia, or hemispatial neglect.
- Presence of hearing, vision, or comprehension impairments that hinder diagnosis and treatment.
- Complicate with traumas, fractures, or other progressive neuro-muscular system diseases.
- Severe spasticity in the upper limbs.
- Severe bone, joint, or muscle deformities or lesions.
- History of mental illness.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: modified mirror therapy+Modified mirror therapy
The study lasted 30 days for each participant.
The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy.
Additionally, the patients in the experimental group were given modified mirror therapy.
|
The routine treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.)
Other Names:
The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
The patients were instructed to watch the recorded video and imitate the movements of their affected limbs.
After the video ended, only the instructions and synchronized music were played.
The patient was required to sit in front of a mirror table, with the mirror placed between both arms and facing the healthy side.
The patient was required to recall the video based on the verbal instructions while using the healthy side to perform movement training.
They were also asked to observe the reflected motion of the healthy limb in the mirror, simultaneously imagining the affected limb moving in sync (the patient focused on the front of the mirror, avoiding direct eye contact with the healthy hand, to create the sensation that it was the affected hand performing the movements).
|
Active Comparator: routine rehabilitation therapy
The study lasted 30 days for each participant.
The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy.
|
The routine treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.)
Other Names:
The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fugl-Meyer Assessment-Upper Extremity
Time Frame: day 1 and day 30
|
The Fugl-Meyer Assessment-Upper Extremity was used to evaluate the patient's upper limb function and motor control.
It included the assessment of movements in the shoulder, elbow joint, wrist, and fingers.
During the assessment, the assessor observed and recorded the patient's abilities and limitations in specific actions.
Based on the patient's performance in each sub-item, the assessor assigned a score using a 0-2 scale, a score of 0 indicating inability to perform, 1 indicating partial ability, and 2 indicating full ability.
Finally, the scores for each sub-item were summed up to obtain an overall upper limb function score of 0-66, with scores positively correlated with the upper limb function.
|
day 1 and day 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the coordinated contraction rate-Surface electromyography-The biceps brachii
Time Frame: day 1 and day 30
|
The surface electromyography (sEMG) was used to assess the coordinated contraction rates of the biceps brachii on the affected upper limb.
The surface electromyography device was used for detection, with the most prominent part of muscle belly of the biceps brachii serving as the monitoring points.
During the maximum isometric voluntary contraction (MIVC) state of elbow flexion or extension, two channels were used to separately record the integrated electromyographic values (iEMG) of the biceps brachii, and the antagonists.
Measurements were taken three times to obtain the maximum value, and the coordinated contraction rate (CR) during elbow flexion or extension under MIVC conditions was calculated using the formula: CR (%) = Antagonist muscle iEMG / (Agonist muscle iEMG + Antagonist muscle iEMG).
|
day 1 and day 30
|
the coordinated contraction rate-Surface electromyography-The triceps brachii
Time Frame: day 1 and day 30
|
The surface electromyography (sEMG) was used to assess the coordinated contraction rates of the triceps brachii on the affected upper limb.
The surface electromyography device was used for detection, with the most prominent part of muscle belly of triceps brachii serving as the monitoring points.
During the maximum isometric voluntary contraction (MIVC) state of elbow flexion or extension, two channels were used to separately record the integrated electromyographic values (iEMG) of the triceps brachii, and the antagonists.
Measurements were taken three times to obtain the maximum value, and the coordinated contraction rate (CR) during elbow flexion or extension under MIVC conditions was calculated using the formula: CR (%) = Antagonist muscle iEMG / (Agonist muscle iEMG + Antagonist muscle iEMG).
|
day 1 and day 30
|
Visual Analog Scale
Time Frame: day 1 and day 30
|
the pain level of the affected shoulder was measured using the Visual Analog Scale (VAS), with 0 indicating no pain and 10 indicating unbearable severe pain.
The lower score indicated the lighter pain.
|
day 1 and day 30
|
Anxiety
Time Frame: day 1 and day 30
|
The anxiety was assessed using the Generalized Anxiety Disorder-7 (GAD-7), including items related to fear, worry, attention, etc.
The total score ranged from 0 to 21, which was positively correlated with potential anxiety.
In the previous study, the GAD-7 scale demonstrated a Cronbach's α-coefficient of 0.879.
The scores range from 0 to 21.
The higher scores mean a worse outcome.
|
day 1 and day 30
|
Depression
Time Frame: day 1 and day 30
|
The depression was assessed using the Patient Health Questionnaire-9 (PHQ-9), with aspects including mood swings, optimism, sleep quality, appetite, etc.
The total score of PHQ-9 ranged from 0 to 27, which was positively correlated with potential depression.
In the previous study, the PHQ-9 scale demonstrated a Cronbach's α-coefficient of 0.913.The scores range from 0 to 27.The higher scores mean a worse outcome.
|
day 1 and day 30
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nieto Luis, Doctor, Site Coordinator of United Medical Group located in Miami
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2022
Primary Completion (Actual)
July 12, 2023
Study Completion (Actual)
August 31, 2023
Study Registration Dates
First Submitted
December 24, 2023
First Submitted That Met QC Criteria
December 28, 2023
First Posted (Actual)
January 10, 2024
Study Record Updates
Last Update Posted (Estimated)
March 5, 2024
Last Update Submitted That Met QC Criteria
March 2, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-KY-0523-012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
Clinical Trials on Routine treatment
-
GlaxoSmithKlineMacroStatCompleted
-
University of LeipzigRecruiting
-
Affiliated Hospital of Nantong UniversityRecruiting
-
Shanghai 6th People's HospitalRecruitingLung Cancer | Bone Metastases | Single Cell Sequencing TechnologyChina
-
Peking University Third HospitalNot yet recruitingAcute Myocardial Infarction
-
Capital Medical UniversityRecruiting
-
Capital Medical UniversityRecruiting
-
Xuanwu Hospital, BeijingBeijing Tiantan Hospital; West China Hospital; Second Affiliated Hospital of... and other collaboratorsRecruiting
-
Shanghai Mental Health CenterCompleted
-
Riphah International UniversityCompleted